Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/5/1390 |
id |
doaj-1abe9425c94b4f0aa0272b5b5c03d4a3 |
---|---|
record_format |
Article |
spelling |
doaj-1abe9425c94b4f0aa0272b5b5c03d4a32020-11-25T03:26:44ZengMDPI AGJournal of Clinical Medicine2077-03832020-05-0191390139010.3390/jcm9051390Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?Philipp E. Hartrampf0Marieke Heinrich1Anna Katharina Seitz2Joachim Brumberg3Ioannis Sokolakis4Charis Kalogirou5Andreas Schirbel6Hubert Kübler7Andreas K. Buck8Constantin Lapa9Markus Krebs10Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Urology, Martha-Maria Hospital Nuremberg, 90491 Nuremberg, GermanyDepartment of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2) Methods: <sup>68</sup>Ga-PSMA PET/CT scans from <i>n</i> = 21 patients with castration-resistant PCa (CRPC) receiving chemotherapy were identified from our single-centre database. PSMA-TV and TL-PSMA were calculated with Syngo.via (Siemens) as well as the freely available Beth Israel plugin for FIJI (Fiji Is Just ImageJ) before and after chemotherapy. While statistical comparability was illustrated and quantified via Bland-Altman diagrams, the clinical agreement was estimated by matching PSMA-TV, TL-PSMA and relative changes of both variables during chemotherapy with changes in serum PSA (ΔPSA) and PERCIST (Positron Emission Response Criteria in Solid Tumors). (3) Results: Comparing absolute PSMA-TV and TL-PSMA as well as Bland–Altman plotting revealed a good statistical comparability of both software algorithms. For clinical agreement, classifying therapy response did not differ between PSMA-TV and TL-PSMA for both software solutions and showed highly positive correlations with BR. (4) Conclusions: due to the high levels of statistical and clinical agreement in our CRPC patient cohort undergoing taxane chemotherapy, comparing PSMA-TV and TL-PSMA determined by Syngo.via and FIJI appears feasible.https://www.mdpi.com/2077-0383/9/5/1390Prostate-specific membrane antigen (PSMA)metabolic tumour volume (MTV)total lesion PSMAbiomarkersoftwarecomparability |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Philipp E. Hartrampf Marieke Heinrich Anna Katharina Seitz Joachim Brumberg Ioannis Sokolakis Charis Kalogirou Andreas Schirbel Hubert Kübler Andreas K. Buck Constantin Lapa Markus Krebs |
spellingShingle |
Philipp E. Hartrampf Marieke Heinrich Anna Katharina Seitz Joachim Brumberg Ioannis Sokolakis Charis Kalogirou Andreas Schirbel Hubert Kübler Andreas K. Buck Constantin Lapa Markus Krebs Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results? Journal of Clinical Medicine Prostate-specific membrane antigen (PSMA) metabolic tumour volume (MTV) total lesion PSMA biomarker software comparability |
author_facet |
Philipp E. Hartrampf Marieke Heinrich Anna Katharina Seitz Joachim Brumberg Ioannis Sokolakis Charis Kalogirou Andreas Schirbel Hubert Kübler Andreas K. Buck Constantin Lapa Markus Krebs |
author_sort |
Philipp E. Hartrampf |
title |
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results? |
title_short |
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results? |
title_full |
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results? |
title_fullStr |
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results? |
title_full_unstemmed |
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results? |
title_sort |
metabolic tumour volume from psma pet/ct scans of prostate cancer patients during chemotherapy—do different software solutions deliver comparable results? |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2020-05-01 |
description |
(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2) Methods: <sup>68</sup>Ga-PSMA PET/CT scans from <i>n</i> = 21 patients with castration-resistant PCa (CRPC) receiving chemotherapy were identified from our single-centre database. PSMA-TV and TL-PSMA were calculated with Syngo.via (Siemens) as well as the freely available Beth Israel plugin for FIJI (Fiji Is Just ImageJ) before and after chemotherapy. While statistical comparability was illustrated and quantified via Bland-Altman diagrams, the clinical agreement was estimated by matching PSMA-TV, TL-PSMA and relative changes of both variables during chemotherapy with changes in serum PSA (ΔPSA) and PERCIST (Positron Emission Response Criteria in Solid Tumors). (3) Results: Comparing absolute PSMA-TV and TL-PSMA as well as Bland–Altman plotting revealed a good statistical comparability of both software algorithms. For clinical agreement, classifying therapy response did not differ between PSMA-TV and TL-PSMA for both software solutions and showed highly positive correlations with BR. (4) Conclusions: due to the high levels of statistical and clinical agreement in our CRPC patient cohort undergoing taxane chemotherapy, comparing PSMA-TV and TL-PSMA determined by Syngo.via and FIJI appears feasible. |
topic |
Prostate-specific membrane antigen (PSMA) metabolic tumour volume (MTV) total lesion PSMA biomarker software comparability |
url |
https://www.mdpi.com/2077-0383/9/5/1390 |
work_keys_str_mv |
AT philippehartrampf metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults AT mariekeheinrich metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults AT annakatharinaseitz metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults AT joachimbrumberg metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults AT ioannissokolakis metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults AT chariskalogirou metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults AT andreasschirbel metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults AT hubertkubler metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults AT andreaskbuck metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults AT constantinlapa metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults AT markuskrebs metabolictumourvolumefrompsmapetctscansofprostatecancerpatientsduringchemotherapydodifferentsoftwaresolutionsdelivercomparableresults |
_version_ |
1724590827120885760 |